Trial Profile
Phase II Study of Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Apr 2017
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- 27 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Feb 2015 Planned End Date changed from 1 May 2015 to 1 May 2016 as reported by ClinicalTrials.gov
- 09 Feb 2015 Planned primary completion date changed from 1 May 2015 to 1 May 2016 as reported by ClinicalTrials.gov